- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Melatonin: A potential nighttime guardian against Alzheimer’s ; day:11 ; month:8 ; year:2024 ; pages:1-14
Molecular psychiatry ; (11.8.2024), 1-14
- Creator
-
Zhang, Zefan
Xue, Pei
Bendlin, Barbara B.
Zetterberg, Henrik
Felice, Fernanda De
Tan, Xiao
Benedict, Christian
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41380-024-02691-6
- URN
-
urn:nbn:de:101:1-2410292106138.759594751452
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:26 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Zhang, Zefan
- Xue, Pei
- Bendlin, Barbara B.
- Zetterberg, Henrik
- Felice, Fernanda De
- Tan, Xiao
- Benedict, Christian
- SpringerLink (Online service)
Other Objects (12)
Blood-based molecular biomarkers for Alzheimer’s disease
Blood-based biomarkers in Alzheimer’s disease – moving towards a new era of diagnostics
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Fluid biomarkers in Alzheimer’s disease – current concepts
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
Neurofilament light chain as neuronal injury marker – what is needed to facilitate implementation in clinical laboratory practice?
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
Levels of ADAM10 are reduced in Alzheimer’s disease CSF
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
The cerebrospinal fluid biomarker profile in an HIV-infected subject with Alzheimer’s disease
Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer’s disease
Blood-based molecular biomarkers for Alzheimer’s disease
Blood-based biomarkers in Alzheimer’s disease – moving towards a new era of diagnostics
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Fluid biomarkers in Alzheimer’s disease – current concepts
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
Neurofilament light chain as neuronal injury marker – what is needed to facilitate implementation in clinical laboratory practice?
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
Levels of ADAM10 are reduced in Alzheimer’s disease CSF
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
The cerebrospinal fluid biomarker profile in an HIV-infected subject with Alzheimer’s disease
Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer’s disease
Blood-based molecular biomarkers for Alzheimer’s disease
Blood-based biomarkers in Alzheimer’s disease – moving towards a new era of diagnostics
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Fluid biomarkers in Alzheimer’s disease – current concepts
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
Neurofilament light chain as neuronal injury marker – what is needed to facilitate implementation in clinical laboratory practice?
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
Levels of ADAM10 are reduced in Alzheimer’s disease CSF
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
The cerebrospinal fluid biomarker profile in an HIV-infected subject with Alzheimer’s disease